TREM2 sustains microglial expansion during aging and response to demyelination

Pietro Luigi Poliani,1 Yaming Wang,2 Elena Fontana,1 Michelle L. Robinette,2 Yoshinori Yamanishi,2 Susan Gilfillan,2 and Marco Colonna2

1Department of Molecular and Translational Medicine, Pathology Unit, University of Brescia School of Medicine, Brescia, Italy. 2Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.

Microglia contribute to development, homeostasis, and immunity of the CNS. Like other tissue-resident macrophage populations, microglia express the surface receptor triggering receptor expressed on myeloid cells 2 (TREM2), which binds polyanions, such as dextran sulphate, bacterial lipooligosaccharides, and various phospholipids (6–8). It transmits intracellular signals through an associated transmembrane adapter, DAP12, which contains tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain (9). DAP12 ITAMs recruit the protein tyrosine kinase Syk, which mediates the phosphorylation of PLC-γ, PI3K, Vav2/3, and other downstream molecules that trigger cell activation (10). Besides directly triggering tyrosine phosphorylation, the TREM2/DAP12 complex cooperates with CSF-1 receptor (CSF-1R) signaling (11), while it interferes with TLR signaling (12–14).

Individuals homozygous for rare inactivating mutations in TREM2 or TYROBP, which encodes DAP12, develop a lethal early onset dementia known as Nasu-Hakola disease. How TREM2 deficiency mediates demyelination and disease is unknown. Here, we addressed the basis for this genetic association using Trem2−/− mice. In WT mice, microglia expanded in the corpus callosum with age, whereas aged Trem2−/− mice had fewer microglia with an abnormal morphology. In the cuprizone model of oligodendrocyte degeneration and demyelination, Trem2−/− microglia failed to amplify transcripts indicative of activation, phagocytosis, and lipid catabolism in response to myelin damage. As a result, Trem2−/− mice exhibited impaired myelin debris clearance, axonal dystrophy, oligodendrocyte reduction, and persistent demyelination after prolonged cuprizone treatment. Moreover, myelin-associated lipids robustly triggered TREM2 signaling in vitro, suggesting that TREM2 may directly sense lipid components exposed during myelin damage. We conclude that TREM2 is required for promoting microglial expansion during aging and microglial response to insults of the white matter.

Introduction

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell-surface receptor of the Ig superfamily that is found in microglia, osteoclasts, and other tissue macrophages in vivo (1–3) as well as in monocyte-derived DCs (4), bone marrow–derived macrophages, and macrophage cell lines in vitro (5). TREM2 binds polyanions, such as dextran sulphate, bacterial lipooligosaccharides, and various phospholipids (6–8). It transmits intracellular signals through an associated transmembrane adapter, DAP12, which contains tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain (9). DAP12 ITAMs recruit the protein tyrosine kinase Syk, which mediates the phosphorylation of PLC-γ, PI3K, Vav2/3, and other downstream molecules that trigger cell activation (10). Besides directly triggering tyrosine phosphorylation, the TREM2/DAP12 complex cooperates with CSF-1 receptor (CSF-1R) signaling (11), while it interferes with TLR signaling (12–14).

Individuals homozygous for rare inactivating mutations in either TREM2 or TYROBP, which encodes DAP12, develop a lethal early onset dementia known as Nasu-Hakola disease (NHD) (1). Patients with NHD are asymptomatic through early adulthood, present with neuropsychiatric symptoms in their third and fourth decades, and expire between the ages of 35 and 45 (15). Postmortem analysis of these rare patients has revealed massive gliosis, with pathology predominantly of the subcortical white matter that includes common demyelinating lesions (15).

While generation of myelin depends primarily on oligodendrocytes (ODCs) (16), microglia contribute to myelination by removing damaged myelin sheaths and releasing soluble factors that promote differentiation of ODCs and subsequent remyelination (17–19). Thus, the association between TREM2 deficiency and demyelinating NHD suggests that microglia may require TREM2 for removing damaged myelin and supporting myelin regeneration by ODCs. While DAP12-deficient mice showed thalamic hypomyelinosi with synaptic degeneration (20), the function of TREM2 in myelination remains to be directly investigated. An in vivo study found that reduced expression of TREM2 in a microglia cell line impaired phagocytosis of apoptotic neurons (21). Moreover, an in vivo study showed that intravenous injection of bone marrow–derived myeloid cells overexpressing TREM2 during experimental autoimmune encephalomyelitis, a model of immune-mediated demyelination, curbed disease by promoting the clearance of apoptotic neurons and secretion of IL-10 (22). However, this model may not recapitulate the function of bona fide microglia, either in normal myelination or nonautoimmune demyelinating diseases, such as NHD. In fact, microglia are brain-resident cells that populate the brain during embryogenesis and self renew throughout life (23–25), whereas adoptively transferred myeloid cells reach the CNS only when inflammation disrupts the blood-brain barrier (26).

Here, we addressed the impact of TREM2 deficiency on brain-resident microglia in vivo during aging and in a model of...
nonautoimmune demyelination, the cuprizone model, which is characterized by apoptosis of mature ODCs, followed by recruitment of astrocytes and activation of brain-resident microglia to remove myelin debris (27, 28). We found that total numbers and density of microglia increased with age in various regions of the brain in WT mice, as previously reported (29–31), whereas age-matched Trem2−/− mice had fewer microglia. After cuprizone challenge, Trem2−/− microglia failed to activate transcriptional programs that promote myelin removal and repair, such as lipid/fatty acid capture, transport, and metabolism, as well as those encoding chemoattractants, inflammatory mediators, and trophic factors for ODCs. Impaired microglial activation was associated with prolonged microgliosis, likely stimulated by persistence of myelin debris, as well as impaired repopulation of OCDs and subsequent remyelination. Moreover, a TREM2 reporter assay showed that TREM2 detects lipidic components of myelin, suggesting that TREM2 directly senses myelin damage. We postulate that TREM2 is a lipid sensor that is essential to promoting microglial activation in response to insults to the white matter.

Results

TREM2 deficiency affects microglial numbers during aging. NHD becomes clinically apparent in presenile individuals, and the underlying pathological changes are recorded postmortem. However, it is not known at which point in life TREM2 deficiency begins to affect microglia and myelination. To address this question, we stained brain sections of 6-month-old, 1-year-old, and 2-year-old WT and Trem2−/− mice for ionized calcium-binding adapter molecule 1 (Iba-1), which is a marker commonly used to identify microglia in the CNS. WT mice had a progressive increase in microglia over time, which was highly significant in the white matter, particularly in the corpus callosum (P < 0.0001) and the cerebellum (P < 0.01), but not in the cerebral cortex (Figure 1, A and B). Although Trem2−/− mice showed microglial numbers similar to WT mice at 6 months, no obvious increase occurred over time. In fact, microglia were significantly less abundant in 2-year-old Trem2−/− mice than in age-matched WT mice, especially in the corpus callosum, cerebellum, and hippocampus (P < 0.0001, P < 0.01, P < 0.05) (Figure 1, A and B). Additionally, microglia in 2-year-old Trem2−/− mice showed dystrophic morphology characterized by smaller cell body and reduced ramifications (Figure 1B, insets, and Figure 1C). Measurement of Iba-1+ areas confirmed a progressive shrinking of the cell body of TREM2-deficient microglia (Figure 1D). Thus, TREM2 deficiency affects long-term numbers and morphology of microglia. These results are reminiscent of those we previously reported for microglia in 1-year-old Dap12−/− mice, which are present in lower numbers and have abnormal morphology compared with WT mice (11). Despite microglial defects, TREM2 deficiency was not associated with marked demyelination, neuronal loss, other marked histological changes, or obvious behavioral abnormalities in aged mice (data not shown), suggesting that a deficit of TREM2 in mouse is not sufficient to cause pathological changes equivalent to human NHD.

TREM2 is required for myelin debris removal and remyelination after cuprizone-induced demyelination. As Trem2−/− mice did not develop spontaneous demyelination, we wanted to determine whether TREM2 deficiency increases susceptibility to induced demyelination. To address this question, we chose to study the cuprizone model of demyelination, in which cuprizone exposure induces apoptosis of mature ODCs, demyelination in the CNS, recruitment of astrocytes, and activation of brain-resident microglia without damaging the blood-brain barrier (27, 28). In this model, there is no confounding infiltration of bone marrow-derived myeloid cells (26, 32). WT and Trem2−/− mice were fed a diet containing 0.2% cuprizone. Mice were analyzed at 4 weeks, the peak of demyelination, or at 12 weeks, at which point both demyelination and remyelination occur. Some groups of mice were fed a normal diet for 2 additional weeks after 4 or 12 weeks of cuprizone treatment to allow myelin recovery. We analyzed myelination of untreated, cuprizone-treated, and recovering mice by transmission electron microscopy (TEM) of the corpus callosum, a sensitive target of demyelination. To precisely quantify the extent of demyelination and remyelination, we measured the ratio of axon circumference to myelin circumference (G ratio). Before cuprizone exposure, the corpus callosum of Trem2−/− mice was myelinated to the same extent as that in the WT mice (Figure 2, A–C). After 4 weeks of cuprizone treatment, WT mice showed clear demyelination, with axonal swelling, increased G ratio, and accumulation of myelin debris (Figure 2, A–C). Myelination returned to normal after 2 weeks of a cuprizone-free diet (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI77983DS1). Like WT mice, Trem2−/− mice showed a clear demyelination at 4 weeks (Figure 2, A–C), which was repaired after 2 weeks of a cuprizone-free diet (Supplemental Figure 1). After 12 weeks of cuprizone treatment, WT mice showed partial demyelination, suggesting ongoing remyelination, which became complete after 2 weeks of a cuprizone-free diet (Figure 2, A–C). In contrast, the corpus callosum of Trem2−/− mice remained largely demyelinated and showed abundant accumulation of myelin debris, which persisted even after the 2-week recovery period (Figure 2, A–C). Trem2−/− mice showed clear axonal dystrophy, as evinced by the presence of axonal spheroids and increased G ratio throughout the experiment (Figure 2C). These data indicate that TREM2 deficiency has no impact on the initial demyelination, but does affect subsequent remyelination when the cuprizone treatment is prolonged, most likely by impairing myelin removal as well as myelin regeneration.

To corroborate these results, we performed immunohistochemical analysis of myelin basic protein (MBP), a major component of myelin. WT mice showed an initial reduction of MBP staining after 4 weeks of cuprizone treatment, followed by a sharp reduction after 12 weeks and a reconstitution of a normal MBP staining in the recovery phase (Figure 2, D and E). We interpret the MBP reduction at 4 weeks to reflect apoptosis of myelinating ODCs, whereas the sharp MBP reduction at 12 weeks was probably due to the removal of damaged myelin. In Trem2−/− mice, MBP staining also appeared reduced at 4 weeks to levels similar to those of WT, but unlike in WT mice, the sharp reduction in MBP staining was not apparent at 12 weeks and MBP continued to be reduced after 2 weeks of recovery. These data corroborate that TREM2 deficiency results in impaired clearance of damaged myelin after prolonged demyelination,
been reported in CNS cells other than microglia (33, 34), recently published studies demonstrated that Trem2 is specifically expressed in microglia — but not other cells in the CNS — under steady-state conditions (35–37). Moreover, we found that Trem2 was not expressed in astrocytes or ODC precursors after 4 weeks of cuprizone feeding, while its expression in microglia was elevated (Supplemental Figure 2). These data indicate that impact of TREM2 on remyelination is largely through microglia.

To investigate the microglial response to cuprizone-induced demyelination, we stained brain sections for Iba-1 and determined the frequency of Iba-1+ cells. Consistent with previous reports (38), WT mice showed a peak of microgliosis at 4 weeks which hinders subsequent myelin regeneration. This conclusion was supported by immunohistochemical analysis of ODC. WT mice showed a limited reduction of ODCs after 4 and 12 weeks of cuprizone treatment, which stabilized during recovery, whereas Trem2−/− mice showed a progressive and significant ODC reduction during cuprizone treatment and recovery (Figure 2, F and G). We conclude that prolonged treatment of Trem2−/− mice with cuprizone causes a persistent demyelination that mimics that observed in NHD.

Trem2−/− mice show dystrophic microgliosis in response to demyelination. We next sought to define the mechanism of defective remyelination in Trem2−/− mice. Although TREM2 expression has been reported in CNS cells other than microglia (33, 34), recently published studies demonstrated that Trem2 is specifically expressed in microglia — but not other cells in the CNS — under steady-state conditions (35–37). Moreover, we found that Trem2 was not expressed in astrocytes or ODC precursors after 4 weeks of cuprizone feeding, while its expression in microglia was elevated (Supplemental Figure 2). These data indicate that impact of TREM2 on remyelination is largely through microglia.

To investigate the microglial response to cuprizone-induced demyelination, we stained brain sections for Iba-1 and determined the frequency of Iba-1+ cells. Consistent with previous reports (38), WT mice showed a peak of microgliosis at 4 weeks
as indicated by smaller cell bodies, as well as fragmentation, beading, and reduced ramification of microglial processes (Figure 3, C and D). These morphological changes suggested that Trem2–/– microglia are dysfunctional.

TREM2 is required to activate microglial transcriptional programs for myelin clearance and repair. To further determine the impact of TREM2 deficiency on the microglial response to demyelination, we performed gene-expression profiling on microglia of cuprizone treatment, which progressively declined at 12 weeks and returned back to basal levels after recovery (Figure 3, A and B). In Trem2–/– mice, microgliosis was less vigorous at 4 weeks, but persisted throughout the recovery phase (Figure 3, A and B). This unresolved microgliosis may be the consequence of a persisting accumulation of myelin debris. As previously observed in nontreated mice (see Figure 1), Trem2–/– microglia in cuprizone-treated mice also exhibited dystrophic morphology, as indicated by smaller cell bodies, as well as fragmentation, beading, and reduced ramification of microglial processes (Figure 3, C and D). These morphological changes suggested that Trem2–/– microglia are dysfunctional.

TREM2 is required to activate microglial transcriptional programs for myelin clearance and repair. To further determine the impact of TREM2 deficiency on the microglial response to demyelination, we performed gene-expression profiling on microglia

Figure 2. Trem2–/– mice show impaired remyelination after cuprizone treatment. Mice were fed regular chow (control) or 0.2% cuprizone diet for 4 weeks, 12 weeks, or 12 weeks followed by 2 weeks of regular chow (recovery). (A–C) Myelination was assessed by TEM. (A) Strategy used for corpus callosum sectioning is indicated in red. (B) Representative images of corpus callosum in different treatments. Deposition of myelin debris (red arrowheads) and axonal spheroids (white arrowheads) is indicated in Trem2–/– mice. (C) Demyelination and remyelination after cuprizone feeding is measured by changes in G ratios. (D–G) Brain sections were stained for MBP and Olig-2 to detect myelin and ODCs, respectively. Representative images for MBP (D) and Olig-2 staining (F). Percentage reduction of MBP reactivity in the total white matter area (E) and frequencies of Olig-2+ cells (G). *P ≤ 0.05; ***P ≤ 0.001; ****P ≤ 0.0001, 2-way ANOVA. Original magnification, ×6000 (B); ×4 (D); ×20 (F). Scale bars: 5 μm (B); 500 μm (D); 100 μm (F). Data represent 2 to 3 mice (B and C) and 3 to 8 mice (D–G) per group. An average of 10 HPF per mouse were evaluated. Error bars represent mean ± SEM.
The induced genes persist and are further increased throughout cuprizone treatment, others are downregulated at late time points correlating with the ensuing remyelination.

To assess the impact of TREM2 deficiency on the cuprizone-induced transcriptional activation program, we visualized the gene signatures across the entire data set (WT and Trem2–/– microglia). While most transcripts that were downregulated after cuprizone were not greatly affected by TREM2 deficiency, we noticed that many transcripts that were selectively increased at either 4 weeks, 12 weeks, or both 4 and 12 weeks were impaired in Trem2–/– mice (Figure 4C). These included Axl, encoding a phagocytic receptor important for the uptake of myelin debris (39); Apoe, Apoc1, Lpl, and Ch25h, which specify key molecules for lipid transport and metabolism; and Igf1, which is a crucial growth factor for ODC differentiation. We also noticed that a group of transcripts that specifically upregulated at 12 weeks were affected by TREM2 deficiency. These encoded several inflammatory genes, such as Il1b, Ifnb1, Il6, and Il12b. Some of these transcriptional changes were further validated by quantitative PCR (qPCR) (Figure 4D). Together, these data indicate that during cuprizone-induced demyelination, TREM2 is required to activate microglia, prompting their response to myelin products and the induction of genes involved in myelin removal and repair and ODC maturation as well as inflammatory responses.

isolated from brains of WT and Trem2–/– mice that were either untreated (controls) or treated with cuprizone for 4 weeks (peak demyelination) or 12 weeks (prolonged demyelination and partial remyelination). A scatter plot of WT and Trem2–/– microglia isolated from control mice demonstrated similar transcriptional profiles between the 2 genotypes, suggesting that TREM2 deficiency does not have a substantial impact on microglia in steady state (Figure 4A). We next determined the impact of cuprizone treatment on microglial gene transcription during the different stages of demyelination by comparing gene expression among WT mice. We found that a large set of microglial transcripts were upregulated (≥2-fold) at 4 weeks (Figure 4B); some of these transcripts remained elevated or were further upregulated at 12 weeks, whereas others were downregulated or returned to baseline at 12 weeks (Figure 4C). An additional set of transcripts were upregulated de novo at 12 weeks (Figure 4C). We further noticed that many genes had reduced expression at 12 weeks (Figure 4B). These transcripts included some that were initially upregulated at 4 weeks as well as others that were progressively reduced from the beginning of the treatment, but reached a marked downregulation (≤2-fold) only at 12 weeks (Figure 4C). Collectively, these data suggest that cuprizone treatment in WT mice activates a microglial transcriptional program early on, during the acute phase of demyelination. While some of the induced genes persist and are further increased throughout cuprizone treatment, others are downregulated at late time points correlating with the ensuing remyelination.

To assess the impact of TREM2 deficiency on the cuprizone-induced transcriptional activation program, we visualized the gene signatures across the entire data set (WT and Trem2–/– microglia). While most transcripts that were downregulated after cuprizone were not greatly affected by TREM2 deficiency, we noticed that many transcripts that were selectively increased at either 4 weeks, 12 weeks, or both 4 and 12 weeks were impaired in Trem2–/– mice (Figure 4C). These included Axl, encoding a phagocytic receptor important for the uptake of myelin debris (39); Apoe, Apoc1, Lpl, and Ch25h, which specify key molecules for lipid transport and metabolism; and Igf1, which is a crucial growth factor for ODC differentiation. We also noticed that a group of transcripts that specifically upregulated at 12 weeks were affected by TREM2 deficiency. These encoded several inflammatory genes, such as Il1b, Ifnb1, Il6, and Il12b. Some of these transcriptional changes were further validated by quantitative PCR (qPCR) (Figure 4D). Together, these data indicate that during cuprizone-induced demyelination, TREM2 is required to activate microglia, prompting their response to myelin products and the induction of genes involved in myelin removal and repair and ODC maturation as well as inflammatory responses.
TREM2 detects lipid components of myelin. We next sought to determine the potential ligands that may activate TREM2 during demyelination. For this, we expressed mouse TREM2 (mTREM2) and DAP12 in a reporter cell line transfected with a chimeric gene encoding the GFP under the control of nuclear factor of activated T cells–responsive (NFAT-responsive) elements. Engagement of the mTREM2/DAP12 complex in these cells leads to mobilization of intracellular Ca²⁺, which triggers GFP expression. Since TREM2 was shown to detect polyanions and phospholipids (6, 8), we tested lipid components of myelin. We initially incubated mTREM2-DAP12 reporter cells in wells coated with crude lipid extracts obtained from normal mouse brains. Myelin lipids induced GFP expression, which was blocked by the addition of anti-TREM2 mAb (Figure 5, A and B). Control mTREM1-DAP12 reporter cells or parental reporter cells were not activated. Thus, myelin components can trigger TREM2 signaling. To further investigate the specificity of TREM2, we incubated mTREM2-DAP12 reporter cells with purified lipid components of myelin, such as sulfatide, cerebroside, sphingomyelin, and various phospholipids. Many of these lipidic components stimulated TREM2 signaling, with the exception of cerebroside (Figure 5C). These results suggest that TREM2 may detect myelin injury by sensing some of the glycolipids and phospholipids that compose myelin and may be exposed during myelin damage.

Discussion
It has been established that TREM2 is expressed in brain-resident microglia (1, 2, 35) and that TREM2 deficiency causes demyelinating NHD (1). However, the function of TREM2 in brain-resident microglia in vivo and the mechanisms underlying NHD demyelination are poorly understood. Our study demonstrates that TREM2 is a sensor for brain lipidic components that promotes microglial fitness and expansion during normal aging. Indeed, TREM2 deficiency hindered the accumulation of microglia during aging, particularly in the corpus callosum, which is rich in myelin that may provide a major stimulus for TREM2 signaling. Microglia were also defective in the cerebellum and hippocampus, which contain less myelin than the corpus callosum; however, no defect was observed in the cortex. The variable impact of TREM2 signaling in distinct brain regions may depend on their myelin content, the presence of alternative TREM2 ligands, the level of TREM2 expression, and the presence of other receptor-ligand interactions that can com-
The Journal of Clinical Investigation

**Research Article**

Figure 5. Myelin lipids activate mTREM2-NFAT-GFP reporter cells. (A and B) mTREM1, mTREM2, and parental reporter cells were stimulated with crude myelin lipids purified from brains of WT mice with or without the addition of anti-mTREM2 mAb. (A) Representative data show GFP expression examined by flow cytometry 16 hours after stimulation. (B) Results from 3 independent experiments are quantified. Ctl, control. (C) mTREM2 reporter cells were stimulated overnight with various lipids at indicated concentrations, and GFP expression was measured by flow cytometry. Data are representative of 2 independent experiments. Error bars represent mean ± SEM.

We showed that TREM2 signaling sustains multiple microglial transcriptional programs that do not fit the conventional M1/M2 paradigm (41). One of these programs leads to the expression of genes induced by IFN-α/β and inflammatory cytokines, consistent with previous reports (42, 43). Most likely, myelin degradation products enter the microglia and engage innate sensors of damage-associated molecular patterns, which trigger the IFN-α/β, NF-κB, and inflammasome pathways. Another transcriptional program promotes lipid and cholesterol uptake, transport, and processing. The expression of genes for lipid processing is consistent with previous studies (44, 45) and is most likely a consequence of microglia uptake of lipoproteins released during myelin damage. Finally, activated microglia express genes that encode chemokines that attract other glial cells and trophic factors, such as IGF1, that promote differentiation and maturation of ODCs, which in turn mediate remyelination. How TREM2 mediates the induction of these multiple gene programs remains unclear. Given that TREM2 and DAP12 promote macrophage survival in the presence of limited concentrations of CSF-1 (11, 46) and that CSF-1 production in the brain may be limited, especially during neuronal and glial damage, TREM2-deficient microglia may be unfit overall and hence dysfunctional; they simply may not be sufficiently robust to activate the multiple programs required for an effective response to myelin damage. Alternatively, TREM2 may be required as a coreceptor for other activating receptors. As DAP12 is located in lipid rafts, engagement of TREM2 may induce aggregation and mobilization of multiple receptors to lipid rafts (47), thereby facilitating their clustering and activation of multiple signaling pathways.

Very recent studies have shown that individuals heterozygous for a rare variant of TREM2, R47H, have high risk for developing Alzheimer disease (AD) (34, 48, 49). The same variant is a risk factor for Parkinson’s disease (PD) and sporadic amyotrophic lateral sclerosis (ALS) (50, 51). The R47H variant impairs TREM2 lipid recognition (52). Thus, it is possible that the TREM2-dependent mechanisms underlying demyelination, AD, PD, and ALS are similar. We have shown that TREM2-deficient microglia fail to remove damaged myelin; similarly, TREM2 may be required for an effective microglia response to and clearance of β-amyloid plaques and other aggregated prion-like proteins. TREM2 may also be required to sustain microglial trophic function, which has been shown to contribute to neuronal homeostasis in the aging brain (37). Interestingly, it was reported that microglial TREM2 expression is reduced in aged mice (37). It is possible that a progressive decline in TREM2...
expression may also occur during aging in certain areas of the human brain, curtailing microglial numbers and the microglial response to the breakdown of myelin, glial cells, and neurons, which would create fertile ground for neurodegeneration. It will be essential to quantify TREM2 expression in different areas of the mouse and human brain at different ages in future studies.

Our TREM2 reporter assays suggest that mTREM2 may bind a broad array of glycolipids and phospholipids, which may be exposed on damaged myelin sheaths as well as on dying glial cells and neurons. We recently demonstrated that human TREM2 detects a similarly broad range of anionic and zwitterionic lipid ligands (52). However, because cerebroside did not activate mTREM2 signaling, TREM2 ligands may have distinct structural constraints that remain to be defined. It is also unclear whether TREM2 binds lipid components within lipoproteins, exosomes, apoptotic cells, or other supramolecular structures. Recent studies have demonstrated that TREM2 is released from the surface of cells through the consecutive action of ADAM10 and γ-secretase (53, 54). Thus, soluble TREM2 might also contribute to transport, delivery, or metabolism of myelin products. In conclusion, our data demonstrate that TREM2 is a lipid sensor that transmits intracellular signals that promote the overall fitness of microglia during aging as well as their ability to respond to prolonged demyelination. The cuprizone treatment of Trem2−/− mice presented here partially recapitulates the pathology of human NHD. Future studies will determine whether impairment of TREM2 function affects other demyelinating and neurodegenerative diseases.

**Methods**

**Mice and cuprizone treatment.** Generation of Trem2−/− mice has been previously described (13). All mice were bred and housed in the same animal facility. Cuprizone was purchased from Sigma-Aldrich (catalog 14690) and sent to Harlan Laboratories to produce a diet containing 0.2% cuprizone.

**Immunohistochemistry.** Paraffin-embedded brain sections (2 µm thick) were dewaxed, rehydrated, and treated with 0.3% H2O2/methanol to block endogenous peroxidase. Heat-induced antigen retrieval was obtained by microwave treatment or incubation in a methanol to block endogenous peroxidase. Heat-induced antigen retrieval was obtained by microwave treatment or incubation in a methanol. Immunohistochemistry was performed as previously described (55). In brief, sections were stained with rat anti-MBP mAb (clone AB980, Chemicon), rabbit anti-ß-1 polyclonal antibody (Wako Chemicals, catalog 019-19741), and rabbit anti-ß-2 polyclonal antibody (Life Technologies, catalog P21954). Stainings were revealed by Real EnVision Rabbit HRP Labelled Polymer System (Dako) and Rat on Mouse HRP Polymer Kit (Biocare Medical) using 3,3′-diaminobenzidine tetrahydrochloride (0.05%) as a chromogen and hematoxylin as counterstaining. Demyelination was evaluated with a morphometric method by measuring the percentage of demyelinated area over the total area of corpus callosum. A Nikon Eclipse 50i microscope was used to count cells. Changes in MBP and microglia surface areas were measured by an Olympus DP70 camera mounted on an Olympus BX60 microscope, using CellF Imaging software (Soft Imaging System GmbH).

**TEM.** TEM was performed as previously described (55). In brief, brains were perfused with formalin and fixed in formalin overnight. Dissected tissues (1 mm in thickness) were postfixed in buffered OsO4, dehydrated in graded alcohol solutions and propylene, embedded in Epon, and examined by light microscopy after toluidine blue staining. Thin sections cut onto Formvar-coated slot grids and stained with uranyl acetate and lead citrate were examined and recorded with a JEOL 1200 electron microscopy. G ratios were determined by measuring the ratio of circumference of axon over myelin using ImageJ (http://imagej.nih.gov/ij/).  

**Gene expression analysis and qPCR.** Brains from 3 mice were dissected and dissociated using a neuronal tissue dissociation kit (Miltenyi Biotec). Microglia were enriched using mouse CD45 beads (Miltenyi Biotec) followed by FACS sorting of CD45−CD11b+ cells using CD45-eFluor450 (30F-11, eBioscience) and CD11b-APC (M1/70, BD Biosciences — Pharmingen). Astrocytes and ODC progenitors were FACS sorted from the CD45+ fraction using ASCA-1-PE antibody (ASCA-1) and A2B5-APC antibody (105HB29), respectively (Miltenyi Biotec). A FACS Aria II (BD) was used for all FACS-sorting experiments, with greater than 99% purity achieved. Cells were sorted directly into RLT buffer, and RNA was extracted using an RNeasy Micro Kit (QIAGEN). For microarray analyses, hybridization (Affymetrix MoGene 1.0 ST array) and data processing were performed at the Washington University Genome Center. Robust multi-array average (RMA) normalization was used, and genes were prefiltered for expression value of 120 or more. Scatter plots and dot plots were produced using the Multiplot module of GenePattern (Broad Institute). Venn diagrams and heat map were generated from a selected gene list using GENE-E (Broad Institute). The expression of selected gene list was further validated by qPCR using a SYBR Green PCR Master Mix (Bio-Rad) and amplified on an ABI7000 machine (Applied Biosystems). qPCR primers used in this study are listed in Supplemental Table 1.

**Accession numbers.** All original microarray data were deposited in the NCBI’s Gene Expression Omnibus (GEO GSE66926).

**Reporter assay.** 43.1 reporter T cells (56) were stably transfected with mTREM2 or mTREM1 and DAPI2 cDNAs. A monoclonal antimurine TREM2 antibody (13) was used to block TREM2 signaling. To extract myelin lipids, myelin vesicles were generated as previously described (57). Briefly, brain from a WT mouse was homogenized with a Dounce homogenizer and resuspended in 0.25 M sucrose solution, followed by centrifugation onto a sucrose gradient. Crude lipids were extracted from myelin vesicles with methanol. Myelin lipids or other purified lipids dissolved in methanol were coated onto a high-absorbent plate (catalog 442404, Thermo Scientific) and incubated at room temperature for 4 hours to allow methanol evaporation. Reporter cells were added to lipid-coated wells or solvent-treated control wells and assessed after overnight incubation. Reporter activity (%) was defined as percentage of GFP+ cells in lipid-coated wells subtracted from background (percentage of GFP+ cells in solvent-treated wells).

**Statistics.** Data in figures are presented as mean ± SEM. All statistical analysis was performed using Prism (GraphPad). Statistical analysis to compare the mean values for multiple groups was performed using 1-way or 2-way ANOVA with correction for multiple comparisons. Comparison of 2 groups was performed using a 2-tailed unpaired t test (Mann Whitney U test). Values were accepted as significant at P ≤ 0.05.

**Study approval.** All animal studies were approved by the Washington University Animal Studies Committee.
Acknowledgments

P.L. Poliani is supported by Fondazione Cariplo. Y. Wang is supported by the Lilly Innovation Fellowship Award (Eli Lilly and Company). Y. Yamashita is supported by a postdoctoral fellowship for research abroad from the Japan Society for the Promotion of Science. M. Colonna is supported by Knight Alzheimer’s Disease Research Center pilot grant PSO AG05681-30 and the Cure Alzheimer’s Fund. We thank the Genome Technology Access Center in the Department of Genetics (Washington University School of Medicine) for help with gene expression analysis. We thank Robert E. Schmidt, Karen Green, and the Morphology and Metabolic Analysis Core (Diabetes Research Center, Washington University School of Medicine, grant no. NIH DK020579) for assistance with TEM analyses. We thank Takashi Saito (RIKEN) for providing the NFAT-GFP reporter cells.

Address correspondence to: Marco Colonna, Washington University School of Medicine, Department of Pathology and Immunology, 660 S. Euclid Ave., Box 8118, St. Louis, Missouri 63110, USA. Phone: 314.362.0367; E-mail: mcolonna@pathology.wustl.edu.


